2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.Peer-Reviewed Original ResearchSmall cell lung cancerRRx-001Partial responseStable diseaseOverall survivalPrior linesCommon treatment-emergent adverse eventsSingle-arm phase II studyArm phase II studyMulticenter phase II trialTreatment-emergent adverse eventsPhase II studyPhase II trialPlatinum-resistant diseaseCell lung cancerOverall response rateTreat populationII trialPrimary endpointAdverse eventsEtoposide chemotherapyII studyComplete responsePlatinum therapyLung cancer
2018
Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)
Zwicker J, Schlechter B, Stopa J, Liebman H, Aggarwal A, Caughey T, Bauer K, Kuemmerle N, Wong E, Wun T, Mclaughlin M, Puligandla M, Neuberg D, Furie B, Flaumenhaft R. Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). Blood 2018, 132: 985. DOI: 10.1182/blood-2018-99-114946.Peer-Reviewed Original ResearchVenous thromboembolismDay 56Major hemorrhageAdvanced cancerAntithrombotic efficacyCancer patientsHigh riskThrombus formationD-dimer plasma concentrationIncidence of VTEPlasma D-dimer levelsNon-small cell lungPhase II clinical trialPlatelet-dependent thrombin generationPrevent Venous ThromboembolismPhase II studySecond-line chemotherapySymptomatic pulmonary embolismD-dimer levelsLower extremity DVTPhase II trialMonths of initiationLower extremity ultrasoundSoluble P-selectinInitial human studiesQUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.Peer-Reviewed Original Research